Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Lung Cancer Health Center

Font Size

New Progress in Targeted Lung Cancer Therapy

Researchers Report Positive Results With Drugs Matched to a Tumor's Molecular Traits
WebMD Health News
Reviewed by Laura J. Martin, MD

April 19, 2010 (Washington, D.C.) -- New research offers hope that people with lung cancer will live longer if drug therapy is guided by the molecular traits of tumors.

"The goal is to match the correct drug with the right patient, based on the best tumor markers we have," says Roy Herbst, MD, of the University of Texas M.D. Anderson Cancer Center in Houston.

So far, researchers have only shown that so-called targeted drugs seem to shrink tumors better if they are chosen based on tumors' specific molecular traits, or biomarkers.

But there is a hint that these gains will someday translate into living longer, Herbst tells WebMD.

Herbst led the mid-stage trial known as BATTLE, short for Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination. In the study, researchers tested four targeted drugs based on patients' biomarkers.

After eight weeks, tumors shrank or stopped growing in 46% of the patients, all of whom had late-stage lung cancer. Typically, only about 30% of these patients would be expected to respond, Herbst says.

Lung Cancer's Toll

Lung cancer is the nation's No. 1 cancer killer, taking the lives of 160,000 Americans a year.

Targeted therapies such as Herceptin and Gleevec have dramatically improved the survival of breast cancer and leukemia patients, but "we're in the dark ages of lung cancer treatment," says M.D. Anderson's Edwin Kim, MD. He presented the BATTLE findings at the annual meeting of the American Association for Cancer Research.

The study involved 255 people with advanced non-small-cell lung cancer, the most common type of lung cancer.

Until recently, there have been few treatment options; with chemotherapy, patients lived an average of only eight months from diagnosis.

In the study, all the patients underwent biopsies so their tissue could be tested for biomarkers associated with non-small-cell lung cancer.

Patients were given one of four targeted treatments: Tarceva, Zactima, Targretin, or Nexavar.

The best results were seen with Nexavar, Kim says. Already approved for liver and kidney cancer, it targets a mutation in a gene called KRAS that is implicated in many cancers.

Today on WebMD

Broken cigarette
Do you know the myths from the facts?
man with a doctor
Our health check will steer you in the right direction.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
15 Cancer Symptoms Men Ignore
Lung Cancer Risks Myths and Facts
cancer fighting foods
Improving Lung Cancer Survival Targeted Therapy
Lung Cancer Surprising Differences Between Sexes
Pets Improve Your Health
Vitamin D
Lung Cancer Surgery Options